Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of LocteronTM (Poly ActiveTM - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C

NCT00593151 is registered in ClinicalTrials.gov with Biolex Therapeutics, Inc. as lead sponsor.

NCT NCT00593151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00593151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of LocteronTM (Poly ActiveTM - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C
Lead sponsor
Biolex Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2009
Enrollment
32 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c